Asklepios BioPharmaceutical, Inc. (AskBio)

72 articles about Asklepios BioPharmaceutical, Inc. (AskBio)

• Libbie Mansell Joins AskBio as SVP Regulatory Affairs

  7/23/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, announced today that Libbie Mansell, PhD, MBA, RAC, has joined the company as a senior vice president to lead its regulatory affairs operations. “Libbie’s career has spanned the development of small molecules and biologics. She has overseen nine global approvals for significant products, and she has created

• AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing SystemTechnology Brings Together Benefits of AAV and CRISPR While Minimizing Negative Effects That Occur During Gene Editing

  6/23/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Jude Samulski, PhD, President, Chief Scientific Officer and Co-founder, has been awarded an international patent application from the World Intellectual Property Organization (WO/2020/076892) for his regulated gene editing system

• AskBio Announces Appointment of Tim Trost as Chief Financial Officer

  5/19/2020

  Asklepios BioPharmaceutical , Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Trost as Chief Financial Officer. Mr. Trost is a highly accomplished CFO with more than 25 years of experience building, managing and financing emerging life sciences companies. Prior to joining AskBio, Mr. Trost most recently served as CFO at Chimerix (NASDAQ: CMRX), w

• AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases

  4/22/2020

  Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company, announced that it has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research spin-out with expertise and an intellectual property estate for the treatment of neurodegenerative disorders.

• Don Haut, PhD, Joins AskBio as Chief Business Officer

  4/7/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Don Haut, PhD, has been appointed its Chief Business Officer to oversee business development strategy and execution. “

• AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome

  3/18/2020

  Collaboration builds upon preclinical research that demonstrates potential for gene therapy to correct deficiency in UBE3A gene

• Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy

  3/12/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced the appointment of Tim Kelly, PhD, as President of Manufacturing. He will oversee all manufacturing functions at AskBio and its Viralgen affiliate for the production of clinical- and commercial-scale AAV vectors.

• AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product Development

  2/19/2020

  Asklepios BioPharmaceutical, Inc., a leading clinical-stage adeno-associated virus gene therapy company, announced that it has appointed scientific leader Anna Tretiakova, PhD, as Senior Vice President of Product Development.

• AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure

  2/4/2020

  Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor Therapeutics subsidiary today announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101. NAN-101 is a gene therapy that aims to activate protein phosphatase inhibitor 1 (I-1c) to inhibit the activity of protein phosphatase 1 (PP1), a substance that plays an important role in the development of heart failure.

• AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical TrialsMatthew Alsante to Lead Program as Director of Patient Advocacy

  1/29/2020

  Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced AskFirst™, its collaborative program for patients and their families who may benefit from its advances in gene therapy research and potential curative therapies

• AskBio to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/2/2020

  Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Sheila Mikhail, AskBio’s Chief Executive Officer and Co-founder, has been invited to provide an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, in San Francisco.

• AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease

  12/19/2019

  AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease

• MediPines Oxistimulator® Demonstrates Reduced Oxygen Desaturations in Postoperative Patients

  11/19/2019

  Positive Clinical Trial Results Published

• AskBio Receives "Best Venture Funding" Award from Southeast BIO

  11/19/2019

  Recognition highlights $235 million investment fueling growth of company and its industry-leading gene therapy technology platform

• Sheila Mikhail, AskBio CEO and Cofounder, Named Springboard Enterprises' 2019 Northstar Honoree

  10/24/2019

  National award recognizes outstanding entrepreneurial women who lead high-growth companies that are transforming their industries

• Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases

  10/15/2019

  This collaboration brings together AskBio’s leading capsid development, clinical stage AAV vector delivery system, and manufacturing expertise with Editas Medicine’s leading genome editing technologies to potentially develop novel medicines for patients with high unmet need.  

• AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics

  9/17/2019

  Asklepios BioPharmaceutical, Inc. (AskBio), a fully integrated Adeno-Associated Virus (AAV) gene therapy platform company focused on providing curative therapeutics for genetic disorders, has acquired the technology assets of RoverMed BioSciences.

• AskBio Acquires Synpromics Ltd. and Expands its Gene Therapy Technology Portfolio

  8/13/2019

  Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics

• Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation

  8/1/2019

  Vida More than Triples Assets Under Management in Less than Two Years to Approximately $1 Billion Based on Success of Inaugural Fund and Focus on Funding Transformational Science

• AskBio Partners with TPG and Vida Ventures

  4/11/2019

  Leading gene therapy company announces $235 million investment to accelerate growth